[go: up one dir, main page]

AR038141A1 - Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace - Google Patents

Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace

Info

Publication number
AR038141A1
AR038141A1 ARP030100098A ARP030100098A AR038141A1 AR 038141 A1 AR038141 A1 AR 038141A1 AR P030100098 A ARP030100098 A AR P030100098A AR P030100098 A ARP030100098 A AR P030100098A AR 038141 A1 AR038141 A1 AR 038141A1
Authority
AR
Argentina
Prior art keywords
ace inhibitor
stable pharmaceutical
pharmaceutical compositions
include ace
compositions
Prior art date
Application number
ARP030100098A
Other languages
English (en)
Inventor
Kamal Mehta
Deepak Bahl
Ravi Kochhar
Puneet Sharma
Vishnubhotia Nagaprasad
Rajiv Mathur
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of AR038141A1 publication Critical patent/AR038141A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas estables que comprenden inhibidor(es) de ACE y otras sustancias farmacéuticamente activas que son susceptibles a la degradación, así como procesos para la preparación de las mismas y métodos de tratamiento que implican la administración de dichas composiciones. Reivindicación 1: Una composición farmacéutica estables para administración oral de inhibidor(es) de ACE que comprende un núcleo revestido con una capa de inhibidor(es) de ACE. Reivindicación 3: La composición de la reivindicación 1, en la cual el inhibidor de ACE se selecciona del grupo formado por ramipil, quinapril, enalapril, espirapril, lisinopril y benazepril.
ARP030100098A 2002-01-15 2003-01-15 Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace AR038141A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN24DE2002 2002-01-15

Publications (1)

Publication Number Publication Date
AR038141A1 true AR038141A1 (es) 2004-12-29

Family

ID=11097019

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100098A AR038141A1 (es) 2002-01-15 2003-01-15 Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace

Country Status (7)

Country Link
US (1) US20050202081A1 (es)
EP (1) EP1467717A1 (es)
AR (1) AR038141A1 (es)
AU (1) AU2003201071A1 (es)
BR (1) BR0306928A (es)
MX (1) MXPA04006892A (es)
WO (1) WO2003059330A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0301471D0 (en) * 2003-01-22 2003-02-19 Biochemie Gmbh Organic compounds
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
EP1813274B1 (en) * 2004-10-06 2009-12-16 Eisai R&D Management Co., Ltd. Medicinal composition, process for producing the same, and method of stabilizing dihydropyridine compound in medicinal composition
WO2006117803A2 (en) * 2005-03-14 2006-11-09 Devarajan, Padma, Venkitachalam Transmucosal drug delivery systems
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
WO2008001184A2 (en) * 2006-06-26 2008-01-03 Emcure Pharmaceuticals Limited Solid composition
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
IT1393244B1 (it) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
NZ226179A (en) * 1987-09-24 1991-04-26 Merck & Co Inc Controlled porosity osmotic pump for sustained release of pharmaceutical agents
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
BRPI9802144B1 (pt) * 1997-05-30 2017-03-28 Ezequiel Mayorga Jorge dispositivo osmótico multicapa aperfeiçoado
US6569456B2 (en) * 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic

Also Published As

Publication number Publication date
US20050202081A1 (en) 2005-09-15
WO2003059330A1 (en) 2003-07-24
EP1467717A1 (en) 2004-10-20
AU2003201071A1 (en) 2003-07-30
MXPA04006892A (es) 2004-10-15
BR0306928A (pt) 2004-11-09

Similar Documents

Publication Publication Date Title
AR038141A1 (es) Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
DE502004005154D1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
WO2005009357A3 (en) Controlled release compositions
ES2733044T1 (es) Composición farmacéutica que contiene oxicodona y naloxona
EA200701575A1 (ru) Формуляция леветирацетама длительного высвобождения
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
MXPA02007762A (es) Sistema de suministro de farmaco pulsativos temporalizados.
AR060931A1 (es) Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion
UY28438A1 (es) Composicion de un antagonista de vegf y de un agente antiproliferativo
MY143795A (en) Tetrahydropyridoindole derivatives
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
ATE287267T1 (de) Kombinationstherapien mit gefässschädigender aktivität
EA200500871A1 (ru) Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo
DE60138572D1 (de) Methoden und pharmazeutische zusammensetzungen zur wundheilung
WO2007062413A3 (en) Use of parp-1 inhibitors
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
BRPI0408299A (pt) inibidores de catepsina s
EA200500672A1 (ru) Содержащие альфузозин композиции с отсроченным высвобождением
AR064185A1 (es) Composiciones y metodos para tratar las convulsiones

Legal Events

Date Code Title Description
FB Suspension of granting procedure